News

Gilead Sciences has awarded $4 million in funding via its ALL4LIVER grant program to organizations worldwide whose community-based efforts will help the World Health…

Combining ursodeoxycholic acid (UDCA) with elafibranor, an experimental oral therapy for primary biliary cholangitis (PBC), may be the best treatment combination for lessening signs…

The levels of more than 250 proteins are abnormal in lab-grown liver organoids, or mini-livers, derived from a mouse model of progressive familial intrahepatic…

FXR314, an investigational oral therapy, safely and effectively reduced liver fat content in adults with a severe form of fatty liver disease called metabolic…

April 19 is a day set aside to raise awareness of liver diseases such as Alagille syndrome. It’s World Liver Day, a global…

Current screening and treatment strategies won’t allow Canada to eliminate new cases of hepatitis C by 2030, a population modeling study found. That’s the…

Ascletis Pharma will not to pursue further clinical testing of its experimental oral therapy ASC42 for adults with primary biliary cholangitis (PBC). The…

A new mutation in the NR1H4 gene was identified as the cause of progressive familial intrahepatic cholestasis type 5 (PFIC5) in a baby girl…

The approval of Rezdiffra (resmetirom) last month in the U.S. as the first ever treatment for nonalcoholic steatohepatitis (NASH), a severe type of…

Five-year-old Sadie Sellers, who was born with biliary atresia, is the focus of a fundraising event designed to raise awareness of and funds for…